NEW YORK, Sept. 17, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Alder Biopharmaceuticals, Inc. ("Alder" or the "Company") (ALDR) in connection with the proposed acquisition of the Company by H. Lundbeck A/S ("H. Lundbeck," OTCMKTS: HLUYY), a Danish pharmaceutical company. Under the terms of the acquisition agreement, ALDR shareholders will receive $18.00 in cash, plus an additional $2 a share contingent upon approval of Alder's migraine drug, Eptinezumab, by the European Medicines Agency.
If you own ALDR shares and wish to discuss this investigation or have any questions concerning this notice or your rights or interests, visit our website: please contact:
Or please contact:
Joshua Rubin, Esq.
1500 Broadway, 16th Floor
New York, NY 10036
Or follow us on Twitter @MarketsAlert
WeissLaw is investigating whether Alder's Board acted to maximize shareholder value prior to entering into the acquisition agreement. Notably, the Company's highly anticipated drug, Epitnezumab, a treatment for migraines, is scheduled for FDA approval in February of 2020. If approved, it will be the first-to-market therapy of its kind with a lead and significant advantages over similar treatments in development.
Given these facts, WeissLaw is concerned whether the proposed acquisition undervalues the Company, and whether all material information related to the proposed acquisition is fully and fairly disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and derivative actions for violations of corporate and fiduciary duties. We have recovered over a billion dollars for defrauded clients and obtained important corporate governance relief in many of these cases. If you have information or would like legal advice concerning possible corporate wrongdoing (including insider trading, waste of corporate assets, accounting fraud, or materially misleading information), consumer fraud (including false advertising, defective products, or other deceptive business practices), or anti-trust violations, please email us at firstname.lastname@example.org
View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-alder-biopharmaceuticals-inc-300920145.html